

Type 1 and type 2 diabetes management

Tom Pisa*



Introduction

On behalf of the Board of the Diabetes Management (DMT) and my co-editors I am proud to introduce you open access peer-reviewed online journal Diabetes Management. The journal Diabetes Management (ISSN: 1758-1907) started publishing in 2011 and has since then published several high quality papers and reviews. The journal is currently indexed in China National Knowledge Infrastructure (CNKI), Chemical Abstracts Service (CAS), WorldCat, Secret Search Engine Labs and is about to be indexed by PubMed. I am extremely thankful to the Editorial board, our readers and contributors (authors and reviewers) for making this journal a great success. DMT was established with a vision of supporting and promoting research in diabetes research across the world. The objective of DMT is to publish up-to-date, high-quality and original research papers alongside relevant and insightful reviews. As such, the journal aspires to be vibrant, engaging and accessible, and at the same time integrative and challenging. It is our pleasure to announce that during year 2019, all issues of volume 6 were published online on time. The journal encourages broader research perspectives including Clinical Care, Education and Nutrition to fight diabetes. When a licensed product reaches patent expiry

other manufacturers have the option of producing biosimilar versions of the original. Following the introduction of the first examples in 2006 a range of biosimilar products belonging to several therapeutic classes is now available in Europe. Included among endocrine biosimilar products are growth hormone, erythropoietin, and follicle-stimulating hormone. The first biosimilar insulin approval was granted by the EMA for Eli Lilly and Boehringer Ingelheim's insulin glargine (tradename Abasagla, previously Abasria, in the EU) in September 2014. In the USA, the US FDA granted tentative approval for the product (with the provisional trade name Basaglar) in the same year. However, the approval became subject to an automatic 'stay' of up to 30 months as a result of litigation filed by Sanofi claiming patent infringement. Sanofi's blockbuster product Diabetes Management presents findings, analysis and commentary on the battle with Type I and Type II diabetes. Articles published in Diabetes Management address improvements in current therapeutics and patient compliance together with perspectives on future prospects. Coverage focuses on the key objective of stabilizing blood glucose levels in individuals with either form of the disease, and the associated issues of patient co-operation and education. The journal also reflects the frontiers of current research, such as attempts to recreate pancreatic cells through stem cell technology or islet cell transplantation, the development of a vaccine for Type 1 disease and the potential for biomarkers to be used for the detection. The increasing understanding of the molecular basis of the disease and associated genetics will play an important part in future diabetes management. During the calendar year 2019, Journal received a total of 19 manuscripts, out of which 4 articles were rejected in the preliminary screening due to plagiarism or being out of the format and peer review process. Globally articles have been accessed by the research scientists and also cited. Needless to say, any papers that you wish to submit, either individually or collaboratively, are much appreciated and will make a substantial contribution to the early development and success of the journal. Best wishes and thank you in advance for your contribution to the Diabetes Management. I would welcome your contributions and suggestions to take DMT to further heights.